Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies

References

• Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124–136.
   PubMed Web of Science ®Google Scholar
• Joussen AM, Smyth N, Niessen C. Pathophysiology of diabetic macular edema. In: Developments in ophthalmology. 2007. p. 1–12.
   Google Scholar
• Bandello F, Lattanzio R, Zucchiatti I, et al. Pathophysiology and treatment of diabetic retinopathy. Acta Diabetol. 2013;50:1–20.
   PubMed Web of Science ®Google Scholar
• Tarr JM, Kaul K, Chopra M, et al. Pathophysiology of diabetic retinopathy. ISRN Ophthalmol. 2013;2013:343560.
   PubMedGoogle Scholar
• Thomas RL, Dunstan F, Luzio SD, et al. Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the diabetic retinopathy screening service for wales: retrospective analysis. BMJ. 2012;344:e874.
   PubMed Web of Science ®Google Scholar
• Simó R, Hernández C. Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence. - PubMed – NCBI. [cited 2018 Oct 31]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25936649
   Google Scholar
• Wang J-H, Ling D, Tu L, et al. Gene therapy for diabetic retinopathy: are we ready to make the leap from bench to bedside? Pharmacol Ther. 2017;173:1–18.
   PubMed Web of Science ®Google Scholar
• Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556–564.
   PubMed Web of Science ®Google Scholar
• Viswanath K, McGavin DD. Diabetic retinopathy: clinical findings and management. Community Eye Health. 2003;16:21.
   PubMedGoogle Scholar
• Diabetic retinopathy - Symptoms and causes. Mayo clinic. 2015 [cited 2018 Jan 18]. Available from: http://www.mayoclinic.org/diseases-conditions/diabetic-retinopathy/symptoms-causes/syc-20371611
   Google Scholar
• Cantrill HL. The diabetic retinopathy study and the early treatment diabetic retinopathy study. - PubMed – NCBI. [cited 2018 Jan 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/6389409
   Google Scholar
• Diabetic Retinopathy Diagnosis. American academy of ophthalmology. 2017 [cited 2018 Jan 18]. Available from: https://www.aao.org/eye-health/diseases/diabetic-retinopathy-diagnosis
   Google Scholar
• Stitt AW, Anderson HR, Gardiner TA, et al. Diabetic retinopathy: quantitative variation in capillary basement membrane thickening in arterial or venous environments. Br J Ophthalmol. 1994;78:133–137.
   PubMed Web of Science ®Google Scholar
• Balabanov R, Dore-Duffy P. Role of the CNS microvascular pericyte in the blood-brain barrier. J Neurosci Res. 1998;53:637–644.
   PubMed Web of Science ®Google Scholar
• Cogan DG, Kuwabara T. The mural cell in perspective. Arch Ophthal. 1967;78:133–139.
   PubMedGoogle Scholar
• Stitt AW, Gardiner TA, Archer DB. Histological and ultrastructural investigation of retinal microaneurysm development in diabetic patients. Br J Ophthalmol. 1995;79:362–367.
   PubMed Web of Science ®Google Scholar
• Szwergold B, Kappler F, Brown T. Identification of fructose 3-phosphate in the lens of diabetic rats. Science. 1990;247:451–454.
   PubMed Web of Science ®Google Scholar
• Gabbay KH. Hyperglycemia, polyol metabolism, and complications of diabetes mellitus. Annu Rev Med. 1975;26:521–536.
   PubMed Web of Science ®Google Scholar
• Steinmetz PR, Balko C, Gabbay KH. The sorbitol pathway and the complications of diabetes. N Engl J Med. 1973;288:831–836.
   PubMed Web of Science ®Google Scholar
• Barnett PA, Gonzalez RG, Chylack LT, et al. The effect of oxidation on sorbitol pathway kinetics. Diabetes. 1986;35:426–432.
   PubMed Web of Science ®Google Scholar
• Lassègue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol. 2003;285:R277–R297.
   PubMed Web of Science ®Google Scholar
• Hammes HP, Martin S, Federlin K, et al. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Nat Acad Sci. 1992;89:9364.
   Google Scholar
• Peppa M, Uribarri J, Vlassara HG. Advanced glycation end products, and diabetes complications: what is new and what works. Clin Diabetes. 2003;21:186–187.
   Google Scholar
• Hammes HP, Martin S, Federlin K, et al. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U.S.A. 1991;88:11555–11558.
   PubMed Web of Science ®Google Scholar
• Stitt A, Gardiner TA, Anderson NL, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes. 2002;51:2826–2832.
   PubMed Web of Science ®Google Scholar
• Zong H, Ward M, Stitt AW. AGEs, RAGE, and diabetic retinopathy. Curr Diab Rep. 2011;11:244–252.
   PubMed Web of Science ®Google Scholar
• Wang QJ. PKD at the crossroads of DAG and PKC signaling. Trends Pharmacol Sci. 2006;27:317–323.
   PubMed Web of Science ®Google Scholar
• Rosse C, Linch M, Kermorgant S, et al. PKC and the control of localized signal dynamics. Nat Rev Mol Cell Biol. 2010;11:103–112.
   PubMed Web of Science ®Google Scholar
• Xia P, Inoguchi T, Kern TS, et al. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes. 1994;43:1122–1129.
   PubMed Web of Science ®Google Scholar
• Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47:859–866.
   PubMed Web of Science ®Google Scholar
• Nerlich AG, Sauer U, Kolm-Litty V, et al. Expression of glutamine: fructose-6-phosphateamidotransferase in human tissues: evidence for high variability and distinct regulation in diabetes. Diabetes. 1998;47:170–178.
   PubMed Web of Science ®Google Scholar
• Wells L. Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science. 2001;291:2376–2378.
   PubMed Web of Science ®Google Scholar
• Chen Y-Q, Su M, Walia RR, et al. Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem. 1998;273:8225–8231.
   PubMed Web of Science ®Google Scholar
• Goldberg HJ, Scholey J, Fantus IG. Glucosamine activates the plasminogen activator inhibitor 1 gene promoter through Sp1 DNA binding sites in glomerular mesangial cells. Diabetes. 2000;49:863–871.
   PubMed Web of Science ®Google Scholar
• Kadonaga J, Courey A, Ladika J, et al. Distinct regions of Sp1 modulate DNA binding and transcriptional activation. Science. 1988;242:1566–1570.
   PubMed Web of Science ®Google Scholar
• Hart GW. Dynamic O-linked glycosylation of nuclear and cytoskeletal proteins. Annu Rev Biochem. 1997;66:315–335.
   PubMed Web of Science ®Google Scholar
• Kiss L, Szabó C. The pathogenesis of diabetic complications: the role of DNA injury and poly(ADP-ribose) polymerase activation in peroxynitrite-mediated cytotoxicity. Mem Inst Oswaldo Cruz. 2005;100(Suppl 1):29–37.
   PubMedGoogle Scholar
• Obrosova IG, Julius UA. Role for poly(ADP-ribose) polymerase activation in diabetic nephropathy, neuropathy and retinopathy. Curr Vasc Pharmacol. 2005;3:267–283.
   PubMedGoogle Scholar
• Peti-Peterdi J, Kang JJ, Toma I. Activation of the renal renin-angiotensin system in diabetes–new concepts. Nephrol Dial Transplant. 2008;23:3047–3049.
   PubMed Web of Science ®Google Scholar
• Shah C. Diabetic retinopathy: a comprehensive review. Indian J Med Sci. 2008;62:500.
   PubMedGoogle Scholar
• Verma A, Shan Z, Lei B, et al. ACE2 and Ang-(1-7) confer protection against development of diabetic retinopathy. Mol Ther. 2012;20:28–36.
   PubMed Web of Science ®Google Scholar
• Du X-L, Edelstein D, Rossetti L, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Nat Acad Sci. 2000;97:12222–12226.
   PubMed Web of Science ®Google Scholar
• Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature. 2000;404:787–790.
   PubMed Web of Science ®Google Scholar
• Garcia Soriano F, Virág L, Jagtap P, et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med. 2001;7:108–113.
   PubMed Web of Science ®Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813.
   PubMed Web of Science ®Google Scholar
• Kaul K, Hodgkinson A, Tarr JM, et al. Is inflammation a common retinal-renal-nerve pathogenic link in diabetes? Curr Diabetes Rev. 2010;6:294–303.
   PubMedGoogle Scholar
• Hernandez C, Segura RM, Fonollosa A, et al. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med. 2005;22:719–722.
   PubMed Web of Science ®Google Scholar
• Doganay S, Evereklioglu C, Er H, et al. Comparison of serum NO, TNF-α, IL-1β, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye. 2002;16:163–170.
   PubMed Web of Science ®Google Scholar
• Kern TS, Miller CM, Du Y, et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes. 2007;56:373–379.
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125:309–317.
   PubMed Web of Science ®Google Scholar
• Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006;113:1533–1538.
   PubMed Web of Science ®Google Scholar
• Comer GM, Ciulla TA. Pharmacotherapy for diabetic retinopathy. Curr Opin Ophthalmol. 2004;15:508–518.
   PubMedGoogle Scholar
• Ishida S, Usui T, Yamashiro K, et al. VEGF164Is proinflammatory in the diabetic retina. Invest Ophthalmol. 2003;44:2155.
   Google Scholar
• Joussen AM, Poulaki V, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol. 2002;160:501–509.
   PubMed Web of Science ®Google Scholar
• Adamis AP, Shima DT, Yeo KT, et al. Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun. 1993;193:631–638.
   PubMed Web of Science ®Google Scholar
• Wirostko B, Wong T, Simo R. Vascular endothelial growth factor and diabetic complications. Prog Retin Eye Res. 2008;27:608–621.
   PubMed Web of Science ®Google Scholar
• Claesson-Welsh L. Vascular growth factors and angiogenesis. Springer Science & Business Media; 2012.
   Google Scholar
• Bates DO, Curry FE. Vascular endothelial growth factor increases microvascular permeability via a Ca(2)-dependent pathway. Am J Physiol Heart Circ Physiol. 1997;273:H687–H694.
   PubMed Web of Science ®Google Scholar
• Bek T. Diabetic retinopathy. In: New concepts in diabetes and its treatment. Switzerland: Karger. 2000. p. 135–151.
   Google Scholar
• Roy S, Trudeau K, Roy S, et al. Mitochondrial dysfunction and endoplasmic reticulum stress in diabetic retinopathy: mechanistic insights into high glucose-induced retinal cell death. Curr Clin Pharmacol. 2013;8:278–284.
   PubMedGoogle Scholar
• Engerman RL, Kern TS. Retinopathy in animal models of diabetes. Diabetes/Metabolism Rev. 1995;11:109–120.
   PubMedGoogle Scholar
• Simó R, Hernández C, European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab. 2014;25:23–33.
   PubMed Web of Science ®Google Scholar
• Hernández C, Dal Monte M, Simó R, et al. Neuroprotection as a therapeutic target for diabetic retinopathy. J Diabetes Res. 2016;2016:9508541.
   PubMedGoogle Scholar
• Hammes HP, Federoff HJ, Brownlee M. Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Mol Med. 1995;1:527–534.
   PubMed Web of Science ®Google Scholar
• Barber AJ, Lieth E, Khin SA, et al. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest. 1998;102:783–791.
   PubMed Web of Science ®Google Scholar
• El-Remessy AB, Al-Shabrawey M, Khalifa Y, et al. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol. 2006;168:235–244.
   PubMed Web of Science ®Google Scholar
• Gardner TW, Davila JR. The neurovascular unit and the pathophysiologic basis of diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2017;255:1–6.
   PubMed Web of Science ®Google Scholar
• Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight. 2017;2(14).
   Web of Science ®Google Scholar
• Simó R, Stitt AW, Gardner TW. Neurodegeneration in diabetic retinopathy: does it really matter? Diabetologia. 2018;61:1902–1912.
   PubMed Web of Science ®Google Scholar
• Shah JH. Improving diabetes care in the clinic. Delhi, India: JP Medical Ltd; 2014.
   Google Scholar
• Lachin JM, Genuth S, Nathan DM, et al. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial–revisited. Diabetes. 2008;57:995–1001.
   PubMed Web of Science ®Google Scholar
• White NH, Sun W, Cleary PA, et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes. 2010;59:1244–1253.
   PubMed Web of Science ®Google Scholar
• Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Early treatment diabetic retinopathy study research group. Arch Ophthalmol. 1985;103:1796–1806.
   PubMed Web of Science ®Google Scholar
• Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early treatment diabetic retinopathy study research group. Ophthalmology. 1991;98:766–785.
   PubMed Web of Science ®Google Scholar
• Michael M, Ronald K, Marie CG. Renal and Retinal Effects of Enalapril and Losartan in Type. 1 diabetes. N Engl J Med. 2009;361:1410–1411.
   Google Scholar
• Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomized, placebo-controlled trials. Lancet. 2008;372:1394–1402.
   PubMed Web of Science ®Google Scholar
• Sjølie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomized placebo-controlled trial. Lancet. 2008;372:1385–1393.
   PubMed Web of Science ®Google Scholar
• Mohammad G, Siddiquei MM, Othman A, et al. High-mobility group box-1 protein activates inflammatory signaling pathway components and disrupts retinal vascular-barrier in the diabetic retina. Exp Eye Res. 2013;107:101–109.
   PubMed Web of Science ®Google Scholar
• Leal EC, Manivannan A, Hosoya KI, et al. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2007;48:5257–5265.
   PubMed Web of Science ®Google Scholar
• Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366:1227–1239.
   PubMed Web of Science ®Google Scholar
• The ACCORD Study Group and ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233–244.
   PubMed Web of Science ®Google Scholar
• Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet. 2007;370:1687–1697.
   PubMed Web of Science ®Google Scholar
• Zhang X, Bao S, Hambly BD, et al. Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy. Int J Biochem Cell Biol. 2009;41:2368–2371.
   PubMed Web of Science ®Google Scholar
• Kamal AD1, Dixon AN, Bain SC. Safety and side effects of the insulin analogues. - PubMed - NCBI. [cited 2018 Jun 27]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16370962
   Google Scholar
• Berezin A. Metabolic memory phenomenon in diabetes mellitus: achieving and perspectives. - PubMed - NCBI. [cited 2018 Jun 27]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27025794
   Google Scholar
• Romero-Aroca P. Is laser photocoagulation treatment currently useful in diabetic macular edema? Med Hypothesis Discov Innov Ophthalmol. 2015;4:5.
   PubMedGoogle Scholar
• Cagnoni F, Njwe CA, Zaninelli A, et al. Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination. Vasc Health Risk Manag. 2010;6:549.
   PubMedGoogle Scholar
• Jonas JB. Intravitreal triamcinolone acetonide for diabetic retinopathy. - PubMed - NCBI. [cited 2018 Jun 27]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17245081
   Google Scholar
• PKC-DRS2 Group, et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. - PubMed - NCBI. [cited 2018 Jun 27]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16989901
   Google Scholar
• Knickelbein JE, Abbott AB, Chew EY. Fenofibrate and diabetic retinopathy. - PubMed - NCBI. [cited 2018 Jun 30]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27525681
   Google Scholar
• Blinder KJ, Dugel P, Chen S, et al. Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1). Clin Ophthalmol. 2017;11:393.
   PubMed Web of Science ®Google Scholar
• Yacyshyn OK, Lai PFH, Forse K, et al. Tyrosine phosphatase beta regulates angiopoietin-Tie2 signaling in human endothelial cells. Angiogenesis. 2009;12:25–33.
   PubMed Web of Science ®Google Scholar
• Gamble JR, Goings G, Upshaw-Earley J, et al. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res. 2000;87:603–607.
   PubMed Web of Science ®Google Scholar
• Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999;284:1994–1998.
   PubMed Web of Science ®Google Scholar
• Scharpfenecker M, Fiedler U, Reiss Y, et al. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci. 2005;118:771–780.
   PubMed Web of Science ®Google Scholar
• Bolinger MT, Antonetti DA. Moving past Anti-VEGF: novel therapies for treating diabetic retinopathy. Int J Mol Sci. 2016;17:1498.
   PubMed Web of Science ®Google Scholar
• Genentech: Press Releases. [cited 2018 Feb 27]. Available from: https://www.gene.com/media/press-releases/14705/2018-02-11/phase-ii-data-support-potential-for-nove
   Google Scholar
• Patrício JPH, Barbosa JPP, Ramos RMM, et al. Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: implications for clinical practice. Clin Drug Investig. 2013;33:167–183.
   PubMed Web of Science ®Google Scholar
• Maldonado RM, Vianna RNG, Cardoso GP, et al. Intravitreal injection of commercially available ketorolac tromethamine in eyes with diabetic macular edema refractory to laser photocoagulation. Curr Eye Res. 2011;36:768–773.
   PubMed Web of Science ®Google Scholar
• Schoenberger SD, Kim SJ, Shah R, et al. Reduction of interleukin 8 and platelet-derived growth factor levels by topical ketorolac, 0.45%, in patients with diabetic retinopathy. JAMA Ophthalmol. 2014;132:32.
   PubMed Web of Science ®Google Scholar
• Friedman SM, Almukhtar TH, Baker CW, et al. Topical nepafenec in eyes with noncentral diabetic macular edema. Retina. 2015;35:944–956.
   PubMed Web of Science ®Google Scholar
• McCormack PL. Ketorolac 0.45% ophthalmic solution. Drugs Aging. 2011;28:583–589.
   PubMed Web of Science ®Google Scholar
• Solomon K. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery. Ophthalmology. 2001;108:331–337.
   PubMed Web of Science ®Google Scholar
• Krady JK, Basu A, Allen CM, et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and Caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes. 2005;54:1559–1565.
   PubMed Web of Science ®Google Scholar
• Cukras CA, Petrou P, Chew EY, et al. Oral minocycline for the treatment of diabetic macular edema (DME): results of a phase I/II clinical study. Invest Ophthalmol Vis Sci. 2012;53:3865–3874.
   PubMed Web of Science ®Google Scholar
• Wu Y, Chen Y, Wu Q, et al. Minocycline inhibits PARP‑1 expression and decreases apoptosis in diabetic retinopathy. Mol Med Rep. 2015;12:4887–4894.
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Criswell MH, Danis RP, et al. Squalamine lactate reduces choroidal neovascularization in a Laser-Injury model in the rat. Retina. 2003;23:808–814.
   PubMed Web of Science ®Google Scholar
• Higgins RD, Yan Y, Geng Y, et al. Regression of retinopathy by squalamine in a mouse model. Pediatr Res. 2004;56:144–149.
   PubMed Web of Science ®Google Scholar
• Liegl R, Koenig S, Siedlecki J, et al. Temsirolimus inhibits proliferation and migration in retinal pigment epithelial and endothelial cells via mTOR inhibition and decreases VEGF and PDGF expression. PLoS One. 2014;9:e88203.
   PubMed Web of Science ®Google Scholar
• Yagasaki R, Tanimoto Y, Abe K, et al. Anti-angiogenic effects of mammalian target of rapamycin inhibitors in a mouse model of oxygen-induced retinopathy. Biol Pharm Bull. 2014;37:1838–1842.
   PubMed Web of Science ®Google Scholar
• Dugel PU, Blumenkranz MS, Haller JA, et al. A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema. Ophthalmology. 2012;119:124–131.
   PubMed Web of Science ®Google Scholar
• Seto B. Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer. Clin Transl Med. 2012;1:29.
   PubMedGoogle Scholar
• Millen AE, Klein R, Folsom AR, et al. Relation between intake of vitamins C and E and risk of diabetic retinopathy in the atherosclerosis risk in communities study. Am J Clin Nutr. 2004;79:865–873.
   PubMed Web of Science ®Google Scholar
• Chous AP, Richer SP, Gerson JD, et al. The Diabetes Visual Function Supplement Study (DiVFuSS). Br J Ophthalmol. 2016;100:227–234.
   PubMed Web of Science ®Google Scholar
• Salvemini D, Page DC. A nonpeptidyl mimic of superoxide dismutase with therapeutic activity in rats. Science. 1999;286:304–306.
   PubMed Web of Science ®Google Scholar
• Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615–1625.
   PubMed Web of Science ®Google Scholar
• Marchetti V, Menghini R, Rizza S, et al. Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signaling. Diabetes. 2006;55:2231–2237.
   PubMed Web of Science ®Google Scholar
• Ferdinando Giacco MB, Brownlee M, Schmidt AM. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058.
   PubMed Web of Science ®Google Scholar
• Rabbani N, Alam SS, Riaz S, et al. High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomized, double-blind placebo-controlled pilot study. Diabetologia. 2009;52:208–212.
   PubMed Web of Science ®Google Scholar
• Thornalley PJ, Babaei-Jadidi R, Al Ali H, et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia. 2007;50:2164–2170.
   PubMed Web of Science ®Google Scholar
• Szabó C, Biser A, Benko R, et al. Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb/db mice. Diabetes. 2006;55:3004–3012.
   PubMed Web of Science ®Google Scholar
• Khoshnevis M, Sebag J. Pharmacologic vitreolysis with ocriplasmin: rationale for use and therapeutic potential in vitreo-retinal disorders. BioDrugs. 2015;29:103–112.
   PubMed Web of Science ®Google Scholar
• Haller JA, Stalmans P, Benz MS, et al. Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials. Ophthalmology. 2015;122:117–122.
   PubMed Web of Science ®Google Scholar
• Varma R, Haller JA, Kaiser PK. Improvement in patient-reported visual function after ocriplasmin for vitreomacular adhesion: results of the microplasmin for intravitreous injection-traction release without surgical treatment (MIVI-TRUST) trials. JAMA Ophthalmol. 2015;133:997–1004.
   PubMed Web of Science ®Google Scholar
• Li Y-J, Li X-H, Wang L-F, et al. Therapeutic efficacy of a novel non-peptide αvβ3 integrin antagonist for pathological retinal angiogenesis in mice. Exp Eye Res. 2014;129:119–126.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Gong J, Xu Z, et al. Inhibition of pathological retinal angiogenesis by the integrin αvβ3 antagonist tetraiodothyroacetic acid (tetrac). Exp Eye Res. 2012;94:41–48.
   PubMed Web of Science ®Google Scholar
• Hernández C, Bogdanov P, Solà-Adell C, et al. Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes. - PubMed - NCBI. [cited 2018 Oct 31]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28779212
   Google Scholar
• Solinís MÁ, Ángeles Solinís M, Del Pozo-Rodríguez A, et al. Treatment of ocular disorders by gene therapy. Eur J Pharm Biopharm. 2015;95:331–342.
   PubMed Web of Science ®Google Scholar
• Gehlbach P, Demetriades AM, Yamamoto S, et al. Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier. Hum Gene Ther. 2003;14:129–141.
   PubMed Web of Science ®Google Scholar
• Pechan P, Rubin H, Lukason M, et al. Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther. 2009;16:10–16.
   PubMed Web of Science ®Google Scholar
• Lamartina S, Cimino M, Roscilli G, et al. Helper-dependent adenovirus for the gene therapy of proliferative retinopathies: stable gene transfer, regulated gene expression and therapeutic efficacy. J Gene Med. 2007;9:862–874.
   PubMed Web of Science ®Google Scholar
• Ideno J, Mizukami H, Kakehashi A, et al. Prevention of diabetic retinopathy by intraocular soluble flt-1 gene transfer in a spontaneously diabetic rat model. Int J Mol Med. 2007. DOI:10.3892/ijmm.19.1.75
   PubMed Web of Science ®Google Scholar
• Tu L, Wang J-H, Barathi VA, et al. AAV-mediated gene delivery of the calreticulin anti-angiogenic domain inhibits ocular neovascularization. Angiogenesis. 2018;21:95–109.
   PubMed Web of Science ®Google Scholar
• Wenyi W, Yajian D, Gaoen M., et al AAV-CRISPR/Cas9-Mediated depletion of VEGFR2 blocks angiogenesis in vitro. - PubMed - NCBI. [cited 2018 Aug 14]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29204648
   Google Scholar
• Huang X, Zhou G, Wu W, et al. Genome editing abrogates angiogenesis in vivo. Nat Commun. 2017;8:112.
   PubMed Web of Science ®Google Scholar
• Díaz-Lezama, N., Wu Z, Adán-Castro E, et al. Diabetes enhances the efficacy of AAV2 vectors in the retina: therapeutic effect of AAV2 encoding vasoinhibin and soluble VEGF receptor 1. Lab Invest. 2016;96:283–295.
   PubMed Web of Science ®Google Scholar
• Biswal MR, Prentice HM, Dorey CK, et al. A hypoxia-responsive glial cell-specific gene therapy vector for targeting retinal neovascularization. Invest Ophthalmol Vis Sci. 2014;55:8044–8053.
   PubMed Web of Science ®Google Scholar
• Haurigot V, Villacampa P, Ribera A, et al. Long-term retinal PEDF overexpression prevents neovascularization in a murine adult model of retinopathy. PLoS One. 2012;7:e41511.
   PubMed Web of Science ®Google Scholar
• Jiang J, Xia X-B, Xu H-Z, et al. Inhibition of retinal neovascularization by gene transfer of small interfering RNA targeting HIF-1alpha and VEGF. J Cell Physiol. 2009;218:66–74.
   PubMed Web of Science ®Google Scholar
• Le Gat L, Gogat K, Bouquet C, et al. In vivo adenovirus-mediated delivery of a uPA/uPAR antagonist reduces retinal neovascularization in a mouse model of retinopathy. Gene Ther. 2003;10:2098–2103.
   PubMed Web of Science ®Google Scholar
• Igarashi T, Miyake K, Kato K, et al. Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model. Gene Ther. 2003;10:219–226.
   PubMed Web of Science ®Google Scholar
• Auricchio A, Behling KC, Maguire AM, et al. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol Ther. 2002;6:490–494.
   PubMed Web of Science ®Google Scholar
• Ghosh P, Sahoo R, Vaidya A, et al. Role of complement and complement regulatory proteins in the complications of diabetes. Endocr Rev. 2015;36:272–288.
   PubMed Web of Science ®Google Scholar
• Adhi M, Cashman SM, Kumar-Singh R, et al. Adeno-associated virus mediated delivery of a non-membrane targeted human soluble CD59 attenuates some aspects of diabetic retinopathy in mice. PLoS One. 2013;8:e79661.
   PubMed Web of Science ®Google Scholar
• Dominguez JM 2nd, Hu P, Caballero S, et al. Adeno-Associated virus overexpression of Angiotensin-Converting Enzyme-2 reverses diabetic retinopathy in type 1 diabetes in mice. - PubMed - NCBI. [cited 2018 Aug 14].. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27178803
   Google Scholar
• Vacca O, Charles-Messance H, El Mathari B, et al. AAV-mediated gene therapy in Dystrophin-Dp71 deficient mouse leads to blood-retinal barrier restoration and oedema reabsorption. - PubMed - NCBI. [ cited 2018 Aug 14]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27288449
   Google Scholar
• Zhang L, Xia H, Han Q, et al. Effects of antioxidant gene therapy on the development of diabetic retinopathy and the metabolic memory phenomenon. Graefes Arch Clin Exp Ophthalmol. 2015;253:249–259.
   PubMed Web of Science ®Google Scholar
• Xu H, Zhang L, Gu L, et al. Subretinal delivery of AAV2-mediated human erythropoietin gene is protective and safe in experimental diabetic retinopathy. Invest Ophthalmol Vis Sci. 2014;55:1519–1530.
   PubMed Web of Science ®Google Scholar
• Hu B, Zhang Y, Zeng Q, et al. Intravitreal injection of ranibizumab and CTGF shRNA improves retinal gene expression and microvessel ultrastructure in a rodent model of diabetes. Int J Mol Sci. 2014;15:1606–1624.
   PubMed Web of Science ®Google Scholar
• Gong Y, Chang Z-P, Ren R-T, et al. Protective effects of adeno-associated virus mediated brain-derived neurotrophic factor expression on retinal ganglion cells in diabetic rats. Cell Mol Neurobiol. 2012;32:467–475.
   PubMed Web of Science ®Google Scholar
• Ramírez M, Wu Z, Moreno-Carranza B, et al. Vasoinhibin gene transfer by adenoassociated virus type 2 protects against VEGF- and diabetes-induced retinal vasopermeability. Invest Ophthalmol Vis Sci. 2011;52:8944–8950.
   PubMed Web of Science ®Google Scholar
• Shyong M-P, Lee FL, Kuo PC, et al. Reduction of experimental diabetic vascular leakage by delivery of angiostatin with a recombinant adeno-associated virus vector. Mol Vis. 2007;13:133–141.
   PubMed Web of Science ®Google Scholar